Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Revolution drug shows promise in early pancreatic cancer

 April 22, 2026

BioPharma Dive

The findings build on data suggesting Revolution s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.

Clinical DataOncologyRead full story

Post navigation

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial →
← Medicare weight loss drug pilot on ice as insurers decline to contribute

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com